NCT01580488View on ClinicalTrials.gov

A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Psoriasis Vulgaris
Interventions
DRUG

B LEO 35299 20 mg/g cream

once daily application, 3 weeks

DRUG

C LEO 35299 20 mg/g cream

once daily application, 3 weeks

DRUG

E LEO 35299 10 mg/g solution

once daily application, 3 weeks

DRUG

F LEO 35299 10 mg/g solution

once daily application, 3 weeks

DRUG

Daivonex® ointment

once daily application, 3 weeks

DRUG

Daivonex® ointment vehicle

once daily application, 3 weeks

Trial Locations (1)

06202

Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD) - Hôpital l'Archet 2, 151 route Saint-Antoine de Ginestière, Nice

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY